Latest Breaking News On - Etween cstl us14843c1053 - Page 1 : comparemela.com

Q1 2023 revenue increased 57% over Q1 2022 to $42 million Q1 2023 total test reports increased 73% over Q1 2022 Reaffirming full-year 2023 revenue is expected to be between $170-180. | May 3, 2023

United statesFrank stokesDerek maetzoldCastle biosciencesCastle decisiondxCastle biosciences incSee the companyAmerican joint committee on cancerSecurities exchangeNational society for cutaneous medicineArchives of dermatological researchQuarter ended marchCypher barrettCash equivalentsMarketable investmentRecent accomplishments